Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Den Haag, Netherlands Clinical Trials

A listing of Den Haag, Netherlands clinical trials actively recruiting patients volunteers.

RESULTS

Found (112) clinical trials

R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL

This study aims to evaluate whether the addition of lenalidomide to rituximab-maintenance improves progression free survival (PFS) compared to standard rituximab maintenance after induction treatment consisting of R-CHOP + R-HAD versus R-CHOP alone in older patients ( 60 year old) with mantle cell lymphoma. 643 patients will be randomized in ...

Phase

0.0 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

The purpose of this study is to evaluate the overall response rate (ORR) of pemigatinib as a monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma harboring FGF/FGFR alterations.

Phase

0.0 miles

Learn More »

Conventional With Stereotactic Radiotherapy for Pain Reduction and Quality of Life in Spinal Metastases

Study population: patients with painful spinal metastases from solid tumors without spinal cord compression or cord instability. Objective: This study will test the hypothesis that stereotactic radiotherapy gives a better and longer lasting reduction of pain, local control and therewith a better quality of life. This in order to optimize ...

Phase

0.0 miles

Learn More »

The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study

Rationale: Rheumatoid arthritis (RA) is a condition with high impact both on the individual and society. In the context of comparing the effectiveness of existing healthcare interventions in the elderly, RA is a condition highly relevant to the community since it has a strongly negative impact on the quality of ...

Phase

0.0 miles

Learn More »

ENdometrial Cancer SURvivors' Follow-up carE (ENSURE): Less is More?

Background: It has often been hypothesized that the frequency of follow-up for patients with early-stage endometrial cancer could be decreased. However, studies evaluating effects of a reduced follow-up schedule among this patient group are lacking. Objective: Assess patient satisfaction and cost-effectiveness of a less frequent follow-up schedule compared to the ...

Phase N/A

0.0 miles

Learn More »

Omitting Sentinel Node Procedure in Breast Cancer Patients Undergoing Breast Conserving Therapy

STUDY AIM To decrease the number of breast cancer patients receiving over treatment of the axilla, in order to positively influence the axillary morbidity rate and quality of life. PRIMARY OBJECTIVE To determine whether omitting the sentinel lymph node procedure is not inferior to the current axillary staging regimen in ...

Phase N/A

0.0 miles

Learn More »

Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer

KRAS mutations occur in 30% of patients with non-small cell lung cancer, especially adenocarcinoma. For long time KRAS mutation has been related with poor prognosis and poor response to chemotherapy. Recent data however show that this is both not true. It seems that response, progression free survival and overall survival ...

Phase

0.0 miles

Learn More »

Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone Receptor Positive Advanced Breast Cancer

Combining cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors with endocrine therapies in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer has shown to result in substantial improvements in progression-free survival. There is however no evidence that this combination strategy leads to an improved overall ...

Phase

0.0 miles

Learn More »

Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults.

This trial aims to improve the strength of the MRD ( minimal residual disease) response as defined by achieving complete MRD negative response (ie, < 10^-4) after the first consolidation phase including blinatumomab.

Phase

0.0 miles

Learn More »